Meet the leaders and members of the Translational Therapeutics research program at the OSUCCC – James who take basic science research from bench to bedside, turning cancer discoveries into clinical trials.

Leaders

David Carbone, MD, PhD

Dr. Carbone is an expert in the molecular genetics of lung tumors, which includes understanding the specific cells and genetic markers in each patient’s lung cancer and developing treatments and drugs that target specific tumor cells. His research interests, grant support and publications focus on.

Read More

Members

Kin Fai Au, PhD

Kin Fai Au, PhD, is an associate professor in the Department of Biomedical Informatics at The Ohio State University and a member of the Translational Therapeutics Program at the OSUCCC – James, where he works on developing novel statistical and computational methods for analyzing high-throughput

Read More

Leona Ayers, MD

Leona Ayers, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where her research is focused on biospecimens and biorepositories, digital image analysis of tissue features and HIV/AIDS-related lymphoma.

Read More

Xue-feng Bai, MD, PhD

Xue-Feng Bai, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on investigation of tumor immune microenvironment and development of novel immunotherapy. Recently, Dr. Bai published a paper in the Journal of Immunology and found.

Read More

Sujit Basu, MD, PhD

Sujit Basu, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James. His research explores the role of endogenous factors regulating tumor microenvironment, including tumor neovascularization and the development of new therapies.

Read More

Erica Bell, PhD

Erica Bell, PhD, focuses her research on understanding the mechanisms of radiation and chemotherapy resistance and sensitivity. In particular, Dr. Bell is interested in the identification of novel predictive and prognostic molecular biomarkers, specifically biomarkers that can be exploited.

Read More

Erin Bertino, MD

Dr. Bertino is a thoracic oncologist with extensive clinical investigative experience. She has worked closely with her senior colleagues to develop additional investigator initiated trials at Ohio State including working on targeted therapies in NSCLC.

Read More

Marcelo Bonomi, MD

Dr. Bonomi's primary clinical research interests are supportive care, patient outcomes, and cancer immunology with particular interest on patients with head and neck. Currently, his research is focusing on check point blockade with the use of low dose chemotherapy and radiation in difficult to.

Read More

William Carson, III, MD

William Carson, MD is a member of the Translational Therapeutics Program at the OSUCCC – James. Dr. Carson is in the department of surgery, division of surgical oncology with clinical interests in breast cancer, melanoma and general cancer surgery.

Read More

Kevin Cassady, MD

My research focuses on how tumor cells permit selective oncolytic viral replication and how these same pathways influence the viral induced immune mediated response. These studies led to the development of an avirulent HSV/HCMV chimeric virus as an anti-tumor therapeutic that is entering Phase I.

Read More

Arnab Chakravarti, MD

Arnab Chakravarti, MD, is the Max Morehouse Chair of Cancer Research at Ohio State, where he directs the Brain Tumor Program and chairs the Department of Radiation Oncology. A member of the OSUCCC – James Translational Therapeutics Program, he focuses on translational cancer research to identify.

Read More

Jeffrey Chalmers, PhD

Jeffrey Chalmers, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he brings a special perspective from the Chemical and Biomolecular Engineering Department in the College of Engineering. His research aids in the development of fundamental understanding and.

Read More

James Chen, MD

James L. Chen, MD, is a sarcoma medical oncologist at the OSUCCC – James, where he also is a member of the Translational Therapeutics Program.

Read More

Wei Chen, MD, PhD

My main research interests are in digestive system tumors, including colorectal cancer (CRC), pancreatic cancer, hepatocellular carcinoma, and neuroendocrine tumors. CRC is the 3rd most common cancer in both men and women in the US.

Read More

Jordan Cloyd, MD

Dr. Cloyd's research interests focus on the multimodality therapy of gastrointestinal, hepatopancreatobiliary and neuroendocrine tumors. Specifically, he is interested in clarifying treatment sequencing, developing new non-surgical therapies, and identifying predictive and prognostic biomarkers in.

Read More

David Cohn, MD

David Cohn, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on identifying biomarkers for early detection and prevention of ovarian cancer, as well as on the genetics of endometrial (uterine) cancer. Through Dr. Cohn’s research, his.

Read More

Kevin Coombes, PhD

Kevin Coombes, PhD, brings a mathematical perspective to the Translational Therapeutics team at the OSUCCC – James. His research centers on statistical, mathematical and computational methods to process, analyze and understand highly multivariate biological data from high-throughput.

Read More

Timothy Cripe, MD, PhD

As a member of the Translational Therapeutics Program at the OSUCCC – James, Timothy Cripe, MD, PhD, explores biologics and targeted therapeutic agents for non-central-nervous-system solid tumors in children, especially sarcomas and neuroblastoma. Dr. Cripe’s work is focused on developing.

Read More

Mikhail Dikov, PhD

Dr. Dikov’s research broadly relates to the tumor-host interaction, cancer immunology, cancer biology, and tumor microenvironment. Specifically, it is focused on the role of tumor-derived factors in hematopoietic development, immune cell differentiation and function.

Read More

Mary Dillhoff, MD

Dr. Dillhoff is a surgical oncologist with a research interest in upper gastrointestinal, hepatobiliary cancers and neuroendocrine tumors. She performs clinical research in these areas as well as basic science research with collaborators.

Read More

Yizhou Dong, PhD

Yizhou Dong, PhD, is a member of the Translational Therapeutics Programat the OSUCCC – James, where his research group is devoted to drug discovery and delivery for the treatment of cancer, as well as inherited genetic disorders and infectious diseases. Dr. Dong and colleagues integrate their.

Read More

Joelle Fenger, DVM, PhD, ACVIM

As a veterinary oncologist, Dr. Fenger’s work using spontaneous models of cancer in dogs has focused on the comparative biology of canine and human cancers with the goal of identifying common molecular pathways that provide a foundation for translational clinical trials. Her lab previously.

Read More

Jonathan Finlay, MD

Dr. Finlay is an academic pediatric oncologist whose professional focus for over 35 years has been on improving outcomes for children, adolescents and young adults with brain cancer. Since 1991, he have initiated, conducted, completed and published results of six sequential multi-national.

Read More

Wendy Frankel, MD

Wendy Frankel, MD, is a Distinguished University Professor of Pathology and holder of the Ralph W. and Helen Kurtz Chair in Pathology at Ohio State.

Read More

Daniel Gallego Perez, PhD

Dr. Gallego Perez' lab’s research is focused on developing novel micro/nanoscale systems for cancer research and therapeutics. Some of the ongoing projects in the lab include novel nanodevices to interrogate tumor explants at the single cell level, understanding singe-cell interactions between.

Read More

Julie Gastier-Foster, PhD

Julie Gastier-Foster, PhD, is a professor in the departments of Pediatrics and Pathology at Ohio State, where she also is a researcher in the Translational Therapeutics Program at the OSUCCC – James. Dr. Gastier-Foster oversees the Institute for Genomic Medicine Clinical Laboratory at.

Read More

Kalpana Ghoshal, PhD

Kalpana Ghoshal, PhD, is an associate professor in the Department of Pathology at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James. The goal of Dr. Ghoshal’s research program is to understand the role of microRNAs and DNA methylation machinery in.

Read More

Pierre Giglio, MD

Pierre Giglio, MD, is an associate professor in the Department of Neurology at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James, where he focuses on developing neuro-oncology clinical trials centering on newly diagnosed and recurrent glioblastoma, the most

Read More

Rajgopal Govindarajan, DVM, PhD

Dr. Govindarajan’s laboratory is interested in understanding and overcoming drug resistance in pancreatic cancer. His training is in the areas of animal sciences, cancer biology and drug transport-based pharmacokinetics, and has extensively used cell and animal models to evaluate nucleoside and.

Read More

John Grecula, MD

John Grecula, MD, is a professor in the Department of Radiation Oncology at Ohio State and a member of the OSUCCC – James Translational Therapeutics Program, where he focuses his research on radiation oncology. Recently, he contributed to a study that showed how a focally-directed treatment.

Read More

Deliang Guo, PhD

Deliang Guo, PhD, is an associate professor in the Department of Radiation Oncology at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James, where he focuses his work on determining the key molecular targets in cancer metabolism and translating those findings

Read More

Peixuan Guo, PhD

Dr. Guo’s major research interest is to apply RNA nanotechnology for cancer therapy. His lab has developed multifunctional RNA nanoparticles harboring RNA aptamer, siRNA, anti-miRNA, drugs or ribozymes.

Read More

Philip Hart, MD

As a medical pancreatologist, Dr. Hart evaluates and manages patients with the spectrum of benign to malignant pancreatic disorders. Cancer-specific research interests include further understanding the relationship between new-onset diabetes mellitus and pancreatic cancer, as well as early.

Read More

John Hays, MD, PhD

John L. Hays, MD, PhD, is an assistant professor in the Department of Internal Medicine at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James.

Read More

Xiaoming (Shawn) He, PhD

A biomedical engineer, Xiaoming He, PhD, is a member of the OSUCCC – James Translational Therapeutics Program. His research has a variety of practical applications related to cancer treatment, transplantation, and regenerative and reproductive medicines.

Read More

Shuiying Hu,

The overall goal of my research is to evaluate the contribution of solute carriers to cancer drug-induced toxicity profiles, in particular peripheral neuropathy. In addition, I aim to identify chemical inhibitors of critical transporters, and explore novel strategies to ameliorate the incidence.

Read More

Zhiwei Hu, MD, PhD

Zhiwei Hu, MD, PhD, is a member of the OSUCCC – James Translational Therapeutics Program and the co-holder of five U. S.

Read More

Hai Huang, MD

Dr. Huang has spent his career studying the role of the tumor micro-environment in various oncologic disease processes. His other research interests include innate immune and inflammatory responses in liver sterile injury, roles of damage-associated molecular patterns and their pattern recognition.

Read More

Naduparambil Jacob, PhD

A member of the OSUCCC – James Translational Therapeutic Program, Naduparambil K. Jacob, PhD, is the co-holder of two U.

Read More

Samson Jacob, PhD

Samson Jacob, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on epigenetic silencing of tumor suppressors and delineating the role of microRNAs. In particular, he uses cells in culture and animal models to study epigenetic silence.

Read More

Joanne Jeter, MD

Dr. Jeter’s primary research interest is in improving the identification and management of individuals at hereditary risk of cancer. Her clinical practice focuses on patients with germline mutations predisposing to many types of cancer, including breast, ovarian, colon, and skin cancers.

Read More

Sachin Jhawar, MD

Dr. Jhawar's interest is in clinical and translational research related to the study of breast cancer, head & neck cancer, and cutaneous malignancies. He has spent a significant amount of time in the lab assessing combination radiation with immunotherapy (specifically T-VEC) and also uses large.

Read More

Selvendiran Karuppaiyah, PhD

Selvendiran Karuppaiyah, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses primarily on drug-resistant ovarian cancer and ovarian cancer therapeutics. Dr. Karuppaiyah’s current research includes identifying the release and oncogenic.

Read More

Pravin Kaumaya, PhD

As a member of the Translational Therapeutics Program at the OSUCCC – James, Pravin Kaumaya, PhD, focuses his research on directing patient immune systems to recognize and kill their own cancer cells. One of his recent studies of potential therapeutic agents for brain tumors reformatted the.

Read More

Michael Knopp, MD, PhD

Michael Knopp, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he focuses his research on imaging biomarkers for disease characterization and response assessment. Dr. Knopp also studies imaging technology development and validation, and imaging.

Read More

Norman Lehman, MD, PhD

Norman Lehman, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on targeting cell cycle and apoptosis regulators for cancer chemotherapy. He also studies cell signaling in tumor angiogenesis and ubiquitin-dependent regulation of.

Read More

Zihai Li, MD, PhD

Zihai Li, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James and the founding director of the Institute for Immuno-Oncology (IIO), which is dedicated to transforming the OSUCCC – James into a leader in basic and clinical immunology research, including prevention

Read More

David Liebner, MD

Dr. Liebner is currently focused on (1) the development of Clinical Informatics tools that can be used to capture relevant cancer outcomes measures from the Electronic Health Record (EHR) as well as (2) leveraging computational tools (e. g.

Read More

Cheryl London, DVM, PhD

As a veterinarian, Cheryl London, DVM, PhD, brings a special perspective to the Translational Therapeutics Program at the OSUCCC – James. Her research focuses on using spontaneous tumors in dogs and cats as models for human cancer.

Read More

Gwendolen Lorch, DVM, PhD

The overall objective of my research is use canine spontaneous cancer models to explore translational opportunities and refine best practices for use of these models. My research uses interdisciplinary collaborations to evaluate the dog with spontaneous lung cancer as a translational model to.

Read More

Lanchun Lu, PhD

Dr. Lu is an ABR Board Certified faculty medical physicist who specializes in image-guided radiation therapy, Gamma Knife radiosurgery, Linac-based external beam radiation therapy, low and high dose rate brachytherapy. His current research focuses on using Optical Coherence Tomography (OCT) to.

Read More

Thomas Mace, PhD

The goal of my research laboratory is to discover factors and pathways that promote immunosuppression and enhance ant-tumor immunity in gastrointestinal malignancies and diseases (i. e.

Read More

Elaine Mardis, PhD

Elaine Mardis, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where she focuses her research on cancer genomics from a discovery and a translational point of view. In particular, she seeks to identify the best therapeutic approaches to fighting an.

Read More

Edward Martin, Jr., MD

Edward Martin Jr. , MD, is a professor in the Department of Surgery, Division of Surgical Oncology at Ohio State and a member of the Translational Therapeutics Program at the OSUCCC – James.

Read More

Eric Miller, MD, PhD

Dr. Miller's research efforts are focused on radiomics and utilizing functional imaging technologies such as MRI and PET to develop novel biomarkers to predict patient treatment response, developing novel therapies for the prevention of normal tissue toxicity from radiation therapy or exposure,

Read More

Anne Noonan, MD

Dr. Noonan's research includes developing new therapies for solid tumors, in particular for hepatocellular carcinoma due to solid tumors (e. g.

Read More

Michael Oglesbee, DVM, PhD

Michael Oglesbee, DVM, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James. He also serves as chair of the Department of Veterinary Biosciences in The Ohio State University College of Veterinary Medicine.

Read More

Inan Olmez, MD

Glioblastoma (GBM) is highly resistant to standard chemoradiation therapy. While GBM stem cells (GSCs) are believed to be the driver for therapeutic resistance and tumor heterogeneity, their origin is still unknown.

Read More

David O'Malley, MD

David O’Malley, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he focuses his research on identifying novel and innovative therapies for gynecologic cancers. He is involved in clinical trials for experimental treatments and in using standard therapies in.

Read More

Gregory Otterson, MD

Gregory Otterson, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on thoracic malignancies. In particular, he is interested in genetic and epigenetic changes in lung cancers.

Read More

Dwight Owen, MD

Dr. Owen is a medical oncologist specializing in treating patients with thoracic malignancies, including lung cancer, mesothelioma and thymic cancers. His research interests include the use of immunotherapy in patients with thoracic cancers, and developing ways to better identify patients who are.

Read More

Navjot Pabla, PhD

Dr. Pabla’s laboratory is focused on identifying therapeutic targets for kidney diseases. Acute kidney injury and renal cell carcinoma are the two major areas of interest.

Read More

Kamalakannan Palanichamy, PhD

Through his research as a member of the OSUCCC – James Translational Therapeutics Program, Kamalakannan Palanichamy, PhD, seeks to explore transcriptomic, epigenetic, metabolomics, proteomic and genomic profiles of patient biopsies in order to identify the mechanisms of chemo and radiation

Read More

Kyle Perry, MD

Kyle Perry, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on prevention, surgical treatment and outcome improvement of esophageal, gastric and pancreatic cancers. In particular, he works on in vivo studies to improve surgical.

Read More

Raphael Pollock, MD, PhD

Raphael Pollock, MD, PhD, is a practicing surgical oncologist who also serves as director of The Ohio State University Comprehensive Cancer Center (OSUCCC). He is also a member of the Translational Therapeutics Program, where his research focuses on the molecular drivers underlying soft tissue.

Read More

Vinay Puduvalli, MD

Vinay Puduvalli, MBBS, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he focuses on patient-oriented research in preclinical, translational and clinical studies. He is an internationally known expert in the treatment and research of neurological malignancies.

Read More

Bhuvaneswari Ramaswamy, MD

As a member of the Translational Therapeutics Program at the OSUCCC – James, Bhuvaneswari Ramaswamy, MD, is focused on improving outcomes in breast cancer through addressing drug resistance and cancer disparities. One of her current projects focuses on the relationship between prolonged.

Read More

Nilsa Ramirez-Milan, MD

Nilsa Ramirez-Milan, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where she focuses on histopathologic diagnosis of tumors. She is also involved in the technology of preserving tissues for biologic research.

Read More

Raju Raval, MD, DPhil

Raju Raval, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he focuses his research on central nervous system (CNS) malignancies. In particular, he evaluates combinations of immune modulation with radiation therapy in CNS malignancies.

Read More

Alo Ray, PhD

Dr. Alo Ray, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James. Dr. Ray’s research interests include understanding the role of DNA damage repair and cell cycle checkpoint pathways in tumor initiation and progression.

Read More

James Rocco, MD, PhD

James Rocco, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research focuses on head and neck cancer, particularly on the origins of intra-tumor heterogeneity, the development of biomarkers that could guide decisions about therapy, and mechanisms of

Read More

Sameek Roychowdhury, MD, PhD

Sameek Roychowdhury, MD, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where his research team uses genomics to identify optimal therapies for patients, also known as precision oncology. Toward that goal, the team evaluates patients with advanced late-stage.

Read More

Wolfgang Sadee, Dr.rer.nat

Wolfgang Sadee, Dr.rer. nat.

Read More

Chandrani Sarkar, PhD

Dr. Sarkar's research primarily focuses on the investigation of the role of endogenous neuromediators in modulating the microenvironment during metastatic cancer progression. Her primary research focus is to dissect the role played by the endogenous neuroimmune modulators (neurohormones and.

Read More

Patrick Schnell, PhD

Dr. Schnell is a Biostatistics faculty member specializing in clinical trial design and analysis, especially precision medicine, Bayesian designs, and multiple hypothesis testing.

Read More

Manisha Shah, MD

Manisha Shah, MD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where her research focuses on discovering new therapies for neuroendocrine, thyroid and adrenal cancers. In particular, she focuses on phase I, II and III clinical trials, as well as preclinical.

Read More

Alex Sparreboom, PhD

Alex Sparreboom, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where he seeks to improve the long-term outcome of patients by modulating the therapeutic window of widely used chemotherapeutics. His work studies the contribution of solute carriers to.

Read More

Daniel Stover, MD

Daniel Stover, MD is a breast medical oncologist and translational physician-scientist and member of the Translational Therapeutics Program at OSUCCC – James. Dr. Stover’s research focus is resistance to therapy in breast cancer through genomic and computational analyses of patient.

Read More

Vishnu Baba Sundaresan, PhD

Vishnu Baba Sundaresan, PhD, brings an engineering perspective to the OSUCCC – James Translational Therapeutics Program. His research focuses on concept, design, fabrication, advance characterization and modeling of bio-derived materials systems, autonomous self-healing materials, autonomous materials through hierarchical assembly and minimally invasive magnetoelectrical surgical tools.

Read More

Debasish Sundi, MD

Dr. Sundi's research explores the functions of immune suppressive cells in the bladder cancer tumor microenvironment (in particular, myeloid derived suppressor cells, or MDSC), and to identify and block MDSC-specific signaling pathways. In so doing his aim is to overcome therapeutic resistance to.

Read More

Gabriel Tinoco, MD

Dr. Tinoco is an ABIM certified specialist in Medical Oncology, Hematology and Internal Medicine, subspecialized in the care of patients with Sarcomas. His particular research interest focus on precision oncology, translational-based trials, as well as the multidisciplinary comprehensive care of.

Read More

Allan Tsung, MD

Allan Tsung, MD, is the director of the Division of Surgical Oncology at the OSUCCC – James as well as a member of the Translational Therapeutics Program, where his research focuses on examining the role of innate immunity in injury-induced inflammation and the tumor microenvironment of primary

Read More

Michael Tweedle, PhD

As a member of the OSUCCC – James Translational Therapeutics Program, Michael Tweedle, MD, focuses on the creation of new molecularly targeted pharmaceuticals visualized in vivo through diagnostic imaging technologies. He is the holder or co-holder of 38 patents.

Read More

Claire Verschraegen, MD

Dr. Verschraaegen's research interests include drug development, clinical investigation, translational science, melanoma, head & neck, sarcomas, gynecologic cancers, appendiceal cancers and rare tumors.

Read More

Meng Welliver, MD, PhD

The overarching research goal of Dr. Welliver’s lab is to understand the molecular underpinnings of subtypes of cancer and to design individualized, targeted therapy to augment the current standard treatment. Her laboratory training included DNA repair, cancer metabolism and cancer cell death.

Read More

Susanne Wells, PhD

Susanne Wells, PhD, is a member of the Translational Therapeutics Program at the OSUCCC – James, where her research focuses on understanding human papillomavirus (HPV)-related and unrelated squamous cell carcinoma to develop new approaches to diagnose and treat HPV as a cause of cancer.

Read More

Robert Wesolowski, MD

Robert Wesolowski, MD, is a principal investigator on numerous solid tumor phase I clinical trials in the Division of Medical Oncology at The Ohio State University and a member of the Translational Therapeutics Program at the OSUCCC – James. His research is focused on conducting early phase.

Read More

Julia White, MD

Julia White, MD, is a member of the Translational Therapeutics Program at OSUCCC – James, where her research focuses on new methods to individualize breast radiation treatment. In particular, she works on developing and implementing new technologies such as prone, conformal, partial breast and.

Read More

Nicole Williams, MD

I am a medical oncologist specializing in Breast Cancer. My research interest include treating older patients diagnosed with breast cancer and brain metastases from breast cancer.

Read More

Chadwick Wright, MD, PhD

Dr. Wright's research interests include (1) cancer imaging with clinical nuclear medicine techniques, (2) PET radioisotope-based optical imaging techniques (i. e.

Read More

Jianqiang Wu, MD

Dr. Wu's specializes in preclinical therapeutic trials on neurofibroma; cancer stem cell(s) in neurofibroma

Read More

Ronald Xu, PhD

Dr. Xu's research includes: (1) Ultrasound and near infrared dual-mode imaging of breast cancer (2) Multimodal microbubbles for cancer targeting and imaging (3) Heat sensitive microbubbles for cancer ablation margin imaging (4) Drug-loaded microbubbles for image-guided combinatory

Read More

Jack Yalowich, PhD

Jack Yalowich, PhD, is a member of the Translational Therapeutics Program at OSUCCC – James, where his research focuses on therapeutic treatment and prevention of cancers. In particular, he is exploring how to improve ability of the clinically effective anticancer agent etoposide (VP-16) in.

Read More

Alper Yilmaz, PhD

Dr. Yilmaz’ lab is developing a navigation system for assisting surgeons to visualize perioperative images and define better tumor margins in real time during the surgery. The system uses preoperative images to locate 3D cancer margins.

Read More

Jun Zhang, PhD

Dr. Zhang’s research includes the development of medical imaging methodologies for effective cancer therapies and improved medical drug development; evaluation of low dose PET and PET imaging acceleration for clinical oncologic PET/CT without compromising qualitative and quantitative image

Read More

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

OR

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Find a Scientific Publication

Search for Clinical Trials